Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 6/20 | 0.40 |
| ▸ | EDNRA | P25101 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310915 | 0.98 | EDNRB (0.41) | EDNRBEDNRAMAPTCNR2DRD4 | |
| SCHEMBL4315006 | 0.97 | EDNRB (0.41) | EDNRBEDNRAMAPTCNR2DRD4 | |
| SCHEMBL4307939 | 0.96 | MAPT (0.41) | EDNRBEDNRAMAPTLMNATSPO | |
| SCHEMBL4321794 | 0.95 | PTGDR2 (0.41) | EDNRBEDNRAMAPTCNR2LMNA | |
| SCHEMBL4308803 | 0.94 | CNR2 (0.40) | EDNRBMAPTCNR2 | |
| SCHEMBL4312789 | 0.94 | TP53 (0.40) | EDNRBMAPTCNR2LMNATSPO | |
| SCHEMBL4310405 | 0.92 | EDNRB (0.38) | EDNRBEDNRAMAPTCNR2DRD4 | |
| SCHEMBL4307784 | 0.92 | EDNRB (0.39) | EDNRBEDNRAMAPTDRD4TSPO | |
| SCHEMBL4307921 | 0.92 | CNR2 (0.38) | EDNRBMAPTCNR2 | |
| SCHEMBL4307678 | 0.91 | EDNRB (0.39) | EDNRBEDNRAMAPTCNR2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-2004193-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | EDNRB 152/4885EDNRA 212/4885MAPT 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.